Get the Stockscreener App
0.1769
4.79%
-0.0089
Azitra Inc stock is traded at $0.1769, with a volume of 1.01M.
It is down -4.79% in the last 24 hours and up +35.97% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.1858
Open:
$0.1817
24h Volume:
1.01M
Relative Volume:
0.09
Market Cap:
$2.86M
Revenue:
$7,500
Net Income/Loss:
$-10.96M
P/E Ratio:
-0.0771
EPS:
-2.2943
Net Cash Flow:
$-11.41M
1W Performance:
+33.21%
1M Performance:
+35.97%
6M Performance:
+1.09%
1Y Performance:
-81.95%
1-Day Range:
$0.1707
$0.1889
1-Week Range:
$0.1281
$0.1889
52-Week Range:
$0.10
$1.09
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.1769 | 2.05M | 7,500 | -10.96M | -11.41M | -2.2943 |
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Azitra Inc Stock (AZTR) Latest News
Azitra (NYSE:AZTR) Strengthens Market Position After Listing Milestone - Kalkine Media
Branford bioscience firm regains NYSE compliance - Hartford Business Journal
Azitra Regains NYSE American Listing Compliance Status - TipRanks
Azitra regains compliance with NYSE American listing standards - Investing.com
Azitra regains compliance with NYSE American li... - Pluang
Azitra Regains NYSE American Compliance; .BC Indicator to Be Removed - TradingView
Azitra (NYSE: AZTR) wins back listing under new NYSE watch period - Stock Titan
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards - PR Newswire
Azitra (AZTR) Earnings Comparison: The Bottom-Line Figure Trails Its Comparison in the Available Record; Post-Report Move: Shares Fall 7.61% in the Latest ReadingROA Comparison - vinanet.vn
Why Is AZTR Stock Rising Today? - Stocktwits
Azitra (AZTR): Nantahala Capital reports 6.48M-share, 9.99% beneficial stake - Stock Titan
Nantahala Capital Partners (AZTR) discloses 8.40% beneficial stake in Azitra - Stock Titan
Azitra, Inc. (AZTR) stock price, news, quote and history - Yahoo Finance Australia
Azitra Reports Q2 Net Loss of $3.3 Million - Quiver Quantitative
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates - PR Newswire
Azitra (NYSE American: AZTR) posts Q2 2026 loss but lifts equity above NYSE limits - Stock Titan
Azitra, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Azitra Q2 FY26 net loss widens to $3.3 million - Bitget
Azitra Inc (AZTR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AZTR Q1 2026 Earnings: EPS Misses Estimates Sharply; No Revenue ReportedProfitability Analysis - vinanet.vn
Azitra Inc (AZTR) Stock News Today - TradingKey
AZTR|Azitra Inc|Price:0.133|Chg%:+0.002 - TradingKey
Azitra Inc Q1 2026 Earnings: Deep EPS Miss Raises Concern as Revenue Remains AbsentProfit Warning Alert - dars.gov.et
Azitra’s ATR12-351 Trial Completion Puts Rare-Disease Skin Drug on Investors’ Radar - TipRanks
AZTR Q1 2026 Earnings: Clinical-stage biotech posts wider-than-expected loss, shares declineRevenue Growth Report - vinanet.vn
Azitra Inc (AZTR) Income Statement - TradingKey
Azitra Inc Revenue Breakdown – AMEX:AZTR - TradingView
Azitra Inc (AZTR) Cash Flow - TradingKey
AZTR|Azitra Inc|Price:0.130|Chg%:+0.003 - TradingKey
Azitra Inc (AZTR) Balance Sheet - tradingkey.com
Azitra Inc (AZTR) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
Azitra Inc (AZTR) Institutional Confidence - TradingKey
Azitra Inc (AZTR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Azitra Inc (AZTR) Tests Key Support at $0.12 After Modest DeclineMomentum Surge Alerts - dars.gov.et
Azitra Inc (AZTR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Azitra Inc (AZTR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Azitra Inc (AZTR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Azitra Inc (AZTR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Azitra Inc (AZTR) Earnings Date & Reports & Earnings News - TradingKey
Azitra Inc (AZTR) Tests Support Near $0.12 Amid Ongoing WeaknessVolume Oscillator - dars.gov.et
AZTR Q1 2026 Earnings: Massive EPS Miss as Clinical-Stage Biotech Reports Wider LossAnnual Financial Report - vinanet.vn
Azitra Inc. (AZTR) surges over 44% after hours—here's why it's trending - MSN
Enterprise value to EBIT forward of Azitra Inc – AMEX:AZTR - TradingView
Price to sales forward of Azitra Inc – AMEX:AZTR - TradingView
Why are shares of Azitra rising? - MSN
Azitra Inc (AZTR) Retreats 6.85% as Stock Tests Key Support at $0.13Volume Breakout Ideas - dars.gov.et
Enterprise value to revenue forward of Azitra Inc – AMEX:AZTR - TradingView
Price to earnings forward of Azitra Inc – AMEX:AZTR - TradingView
AzitraAnnounces Breakthrough Ex Vivo Resul - Moomoo
Azitra, Inc. (NYSE American: AZTR) shows dose-linked skin elasticity gains - Stock Titan
/C O R R E C T I O N -- Azitra, Inc./ - AOL.com
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.37%
0.23%
Cap:
|
Volume (24h):